Metadoxil, 300 mg/5 ml 5 ml 10 pcs

Metadoxyl – detoxifying, hepatoprotective, antialcoholic.

Pharmacodynamics

The hepatoprotective effect of metadoxin is due to membrane stabilizing effect and is based on the ability to restore the ratio of saturated and unsaturated free fatty acids. As a result, the resistance of hepatocytes to the action of lipid peroxidation, which occurs under the influence of various toxic agents, is increased. Metadoxin detoxifying effect is due to the activation of liver enzymes involved in the metabolism of ethanol – alcohol dehydrogenase and acetaldehyde dehydrogenase, which accelerates the elimination of ethanol and acetaldehyde from the body and thus reduces their toxic effects.

Metadoxin prevents accumulation of triglycerides in hepatocytes and also prevents formation of fibronectin and collagen, which significantly slows down the formation of cirrhosis.

The drug reduces mental and somatic manifestations of hangover syndrome, reduces the time of withdrawal syndrome relief.

Metadoxine activates cholinergic and GABAergic neurotransmitter systems, improves thinking and short-term memory functions, prevents motor agitation caused by ethanol.

Metadoxine has nonspecific antidepressant and anxiolytic effects, reduces craving for alcohol.

Pharmacokinetics

It is rapidly absorbed from the gastrointestinal tract and has high bioavailability (60-80%). Binding to plasma proteins is 50%. It is metabolized in liver to active metabolites – pyridine and pyrrolidone carboxylate. T1/2 is 40-60 min when administered orally or by parenteral injection. 45-50% of the drug is excreted in the urine within 24 hours, 35-50% of the drug is excreted in the feces within 96 hours.

Indications

complex therapy of liver diseases, especially alcohol etiology;
acute alcohol intoxication;
chronic alcoholism;
alcohol withdrawal syndrome.

Pharmacological effect

Metadoxil – detoxification, hepatoprotective, anti-alcohol.

Pharmacodynamics

The hepatoprotective effect of metadoxine is due to the membrane-stabilizing effect and is based on the ability to restore the ratio of saturated and unsaturated free fatty acids. As a result, the resistance of hepatocytes to the action of lipid peroxidation, which occurs when exposed to various toxic agents, increases. The detoxification effect of metadoxine is due to the activation of liver enzymes involved in the metabolism of ethanol – alcohol dehydrogenase and acetaldehyde dehydrogenase, which accelerates the process of removing ethanol and acetaldehyde from the body, and consequently, their toxic effects are reduced.

Metadoxine prevents the accumulation of triglycerides in hepatocytes, and also prevents the formation of fibronectin and collagen, which significantly slows down the process of formation of liver cirrhosis.

The drug reduces the mental and somatic manifestations of hangover syndrome, reduces the time of relief of withdrawal symptoms.

Metadoxine activates the cholinergic and GABAergic neurotransmitter systems, improves the functions of thinking and short memory, and prevents the occurrence of motor excitation, which is caused by ethanol.

Metadoxine has a nonspecific antidepressant and anxiolytic effect, reduces the desire for alcohol.

Pharmacokinetics

It is quickly absorbed from the gastrointestinal tract and has high bioavailability (60–80%). Plasma protein binding – 50%. Metabolized in the liver to active metabolites – pyridine and pyrrolidone carboxylate. T1/2 when taken orally or parenterally is 40–60 minutes. 45–50% of the drug is excreted in the urine within 24 hours, 35–50% of the drug is excreted in the feces within 96 hours.

Active ingredient

Metadoxine

Composition

Active ingredient:

metadoxine (pyridoxine L-2 pyrrolidone 5-carboxylate) 300 mg;

Excipients:

sodium metabisulfite;

sodium edetate;

methyl p-hydroxybenzoate;

water for injections

Pregnancy

Metadoxil is contraindicated during pregnancy and breastfeeding.

Contraindications

hypersensitivity to any component of the drug;
pregnancy;
lactation period.

With caution: use with caution in Parkinson’s disease if levodopa is used concomitantly, because metadoxine reduces the effectiveness of the drug.

The ampoules of the injection solution contain sodium metabisulfite. This substance may cause allergic reactions or worsening of asthma attacks in susceptible people, especially those suffering from bronchial asthma.

Side Effects

Allergic reactions. Patients suffering from bronchial asthma may develop bronchospasm when using the injection solution.

Interaction

When used together, it reduces the effectiveness of levodopa.

Storage conditions

In a place protected from light, at a temperature not exceeding 25 °C.

Shelf life

5 years

Manufacturer

Doppel Pharmaceutici S.R.L., Italy